Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipient

Journal of Clinical Microbiology

Volumn 42, Issue 7, 2004, Pages 3363-3365

  Brandt, Mary E ^a,e   Kauffman, Carol A ^b   Pappas, Peter G ^c   Iqbal, Naureen ^a   Arthington Skaggs, Beth A ^a   Lee Yang, Wendy ^a   Smith, Maudy T ^d  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c University of Alabama at Birmingham   (United States)

^d CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GANCICLOVIR; IFOSFAMIDE; ITRACONAZOLE; LEVOFLOXACIN; MEROPENEM; METHOTREXATE; PREDNISONE; RITUXIMAB; VANCOMYCIN; VINCRISTINE; VORICONAZOLE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANDIDA; CASE REPORT; CLINICAL FEATURE; DRUG SENSITIVITY; FUNGEMIA; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HODGKIN DISEASE; HUMAN; MALE; MYCOSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; YEAST; ZYGOASCUS HELLENICUS;

BASE SEQUENCE; CANDIDA; FUNGEMIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

CANDIDA; FUNGI; ZYGOASCUS HELLENICUS;

EID: 3142708646     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.7.3363-3365.2004     Document Type: Article

References (15)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128.
2. Brandt, M. E., L. E. Benjamin, and G. E. Steinkraus. 2003. Pseudooutbreak of Candida versatilitis fungemia in a microbiology laboratory. Diagn. Microbiol. Infect. Dis. 46:73-75.
3. Gorin, P. A. J., and J. F. T. Spencer. 1970. Proton magnetic resonance spectroscopy - an aid in identification and taxonomy of yeasts. Adv. Appl. Microbiol. 13:25-89.
4. Hajjeh, R. A., A. N. Sofair, L. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. A. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. Thomson Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
5. Hazen, K. C. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:462-478.
6. Kao, A. S., M. E. Brandt, W. R. Pruitt, L. A. Conn, B. A. Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two U.S. cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.
7. Kurtzman, C. P., and C. J. Robnett. 1997. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 5′ end of the large subunit (26S) ribosomal DNA gene. J. Clin. Microbiol. 35:1216-1223.
8. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and bone marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
9. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
11. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, R. N. Jones. and the International Fungal Surveillance Participant Group. 2003. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J. Clin. Microbiol. 41:78-83.
12. Rex, J. H., M. A. Pfaller, T. J. Walsh, V. Chaturvedi, A. Espinel-Ingroff, M. A. Ghannoum, L. L. Gosey, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, and D. W. Warnock. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658.
13. Rex, J. H., M. A. Pfaller, A. L. Barry, P. W. Nelson, and C. D. Webb. 1995. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
14. Smith, M. T. 1998. Zygoascus, p. 422-423. In C. P. Kurtzman, and J. W. Fell (ed.), The yeasts - a taxonomic study, 4th ed. Elsevier Science, Amsterdam, The Netherlands.
15. Wingard, J. R. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.